Skip to main content

Table 2 Treatment characteristics and follow-up of 91 patients with dermatomyositis

From: Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study

Characteristics

N = 91

Current follow-up

75 (83.3)

Duration of follow-up (months)

44 (17–67)

Disease status at the last medical evaluation

 

 Active disease (clinical relapse)

30 (33.0)

 Complete clinical response

44 (48.4)

 Disease remission

17 (18.7)

Treatment

 

 Previous IVMP pulse therapy

70 (76.9)

 Previous IVIg

54 (59.3)

 Previous IVIg + IVMP pulse therapy

50 (54.9)

 No IVMP or IVIg

14 (15.4)

Current treatment

 

 Glucocorticoid

 

  Current use

30 (33.0)

  Current dose (prednisone equivalent), mg/day

0.0 (0.0–7.5)

Immunosuppressive/immunomodulatory/immunobiological

 

 Methotrexate

21 (23.1)

 Azathioprine

12 (13.2)

 Mycophenolate mofetil

12 (13.2)

 Leflunomide

8 (8.8)

 Cyclosporine

3 (3.3)

 Cyclophosphamide

1 (1.1)

 Rituximab

30 (33.0)

  1. IVIg, intravenous immunoglobulin; IVMP, intravenous methylprednisolone
  2. Data are expressed as mean ± standard deviation, median (IQR 25th–75th), or percentage (%)